Bal Raju Kammari

Bal Raju Kammari

Auto-generated profile, based on publicly available information

Bal Raju Kammari

Polymorph Screening and Development Laboratory, R&D center, MSN Laboratories (P) Ltd., Plot No.12, IDA Pashamylaram, Patancheru, Hyderabad 502307, Telangana, India

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2019 in Chemistry of Materials
Verified
Journal Article
Closed access
RDRamesh Devarapalli
Ramesh Devarapalli
SKSourabh Bhagwan Kadambi
Sourabh Bhagwan Kadambi
CCChun-Teh Chen
Chun-Teh Chen
GKGamidi Rama Krishna
Gamidi Rama Krishna
BKBal Raju Kammari
Bal Raju Kammari
CRC. Malla Reddy
C. Malla Reddy

31 May 2018 in Crystal Growth & Design
Verified
Journal Article
Closed access
KRK. Bal Raju
K. Bal Raju
SRSubham Ranjan
Subham Ranjan
VVV. S. Vishnu
V. S. Vishnu
MBManjima Bhattacharya
Manjima Bhattacharya
BBBiswajit Bhattacharya
Biswajit Bhattacharya
CRC. Malla Reddy
C. Malla Reddy

12 January 2022 in Crystal Growth & Design
Verified
Journal Article
Closed access
VSVenkata Narasayya Saladi
Venkata Narasayya Saladi
BKBal Raju Kammari
Bal Raju Kammari
PMPratap Reddy Mandad
Pratap Reddy Mandad
GKGamidi Rama Krishna
Gamidi Rama Krishna
ESEswaraiah Sajja
Eswaraiah Sajja
VMVijayavitthal Thippannachar T Mathad
Vijayavitthal Thippannachar T Mathad

15 February 2022 in ACS Omega
Verified
Journal Article
Open access
VSVenkata Narasayya Saladi
Venkata Narasayya Saladi
BKBal Raju Kammari
Bal Raju Kammari
AMArthanareeswari Maruthapillai
Arthanareeswari Maruthapillai
SMSudarshan Mahapatra
Sudarshan Mahapatra
RCRamanaiah Chennuru
Ramanaiah Chennuru
VMVijayavitthal Thippannachar T Mathad
Vijayavitthal Thippannachar T Mathad
Exploration of alternate solid forms for dasatinib, a potent oncogene tyrosine kinase inhibitor classified under Biopharmaceutics Classification System (BCS) class II drugs with low water solubility and high permeability, has been performed using COSMO-RS excess enthalpy (Hex) to increase dissolution. The theoretical prediction resulted in the potential for the formation of C6–C8 fatty acid solvates with dasatinib. A crystallization process has been identified for the preparation of the predicted solvates and successfully scaled up till the 100 g level. The fatty acid solvates are completely characterized using powder X-ray diffraction (PXRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), Fourier transform infrared (FT-IR) spectroscopy, and proton nuclear magnetic resonance (1H NMR) spectroscopy. Unique powder X-ray diffraction patterns and powder indexing of C6–C8 fatty acid solvates indicate the purity of the solid phase. The red shift in the acid carbonyl stretching frequency of C6–C8 fatty acids in FT-IR spectra and the intactness of the fatty acid proton in 1H-NMR spectra provide evidence for solvate formation. The stoichiometry of active pharmaceutical ingredients (APIs) with solvent in solvates is measured using TGA and 1H-NMR spectroscopy. Dasatinib C6–C8 fatty acid solvates were found to retain their solid form under various stress and pharmaceutical processing conditions. In addition, they exhibited improved powder dissolution over dasatinib Form H1-7 by 2.2-fold. They also showed stability at 40 °C and 75% RH for 3 months. C8 fatty acid is a USFDA GRAS listed solvent, and hence may be a viable option for drug product development.

16 October 2023 in Crystal Growth & Design
Verified
Journal Article
Closed access
BKBal Raju Kammari
Bal Raju Kammari
VSVenkata Narasayya Saladi
Venkata Narasayya Saladi
AGAbhijit Garai
Abhijit Garai
RSRajeshwar Reddy Sagyam
Rajeshwar Reddy Sagyam
RSRajan Thirumalai Srinivasan
Rajan Thirumalai Srinivasan
VMVijayavitthal Thippannachar T Mathad
Vijayavitthal Thippannachar T Mathad